
European Commission approves semaglutide tablets for obesity treatment
TV SourceTVN24Warsaw

The European Commission has authorized oral semaglutide in the EU to treat obesity. It will be the first tablet in this class approved in the European Union specifically for this purpose and will be available by prescription only.
The medicine is intended for adults with a body mass index of at least 30, as well as those with a BMI of 27 to 30 and at least one related condition. The tablets are to complement a low-calorie diet and physical activity.
In the OASIS 4 trial, participants taking semaglutide lost an average of 13.6% of their initial body weight over 64 weeks, versus 2.2% in the placebo group. The manufacturer plans a gradual EU rollout in the second half of 2026, but its arrival date in Polish pharmacies, price and possible reimbursement have not yet been announced.
Loading…